Pfizer's dual-acting β₂ agonists/muscarinic M₃ antagonists

Abstract

Bifunctional aromatic compounds that contain both β₂ agonist and muscarinic antagonist pharmacophores linked by a flexible lipophilic spacer are claimed. The compounds display nanomolar potency with respect to both activities and appear designed to provide a long duration of action. The compounds are claimed to be useful in the treatment of both asthma and chronic obstructive pulmonary disease.

Keywords::

• asthma
• β₂ agonist
• bronchodilator
• COPD
• M3 antagonist
• MABA
• muscarinic antagonist